Article
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.
The oncologist - 1 Jan 2017
Socinski Mark A, Villaruz Liza C, Ross Jeffrey
Abstract excerpt
Molecular profiling and the discovery of drugs that target specific activating mutations have allowed the personalization of treatment for non-small cell lung cancer (NSCLC). The epithelial growth factor receptor (EGFR) is frequently over-expressed and/or aberrantly activated in different cancers, including NSCLC. The most common activating mutations of EGFR in NSCLC fall within the tyrosine kinase-binding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
